Vera Therapeutics (VERA) Earnings Analysis

Vera Therapeutics (VERA) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it missed with EPS -1.69 USD vs -1.32838 USD est (-27.2%). It has beaten estimates in 1/5 recent quarters (20%). Trailing P/E -6.51.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does VERA next report earnings?

No confirmed upcoming earnings date is currently scheduled for VERA. This page updates as the calendar is published.

VERA earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-1.69 USD-1.32838 USD-27.2%Miss
2026-02-26-1.39 USD-1.34 USD-3.7%Miss
2025-02-26-0.72 USD-0.83 USD+13.3%Beat
2024-11-07-0.85 USD-0.69 USD-23.2%Miss
2024-08-08-0.62 USD-0.58 USD-6.9%Miss

Beat rate: 1/5 (20%) over reported quarters with consensus data.

VERA valuation and analyst view

Trailing P/E-6.51
Trailing EPS-5.16187 USD
Price / book5.16
Dividend yield0.00%
Market cap2.60B
Analyst consensusBuy (13 buy / 1 hold / 0 sell)
Avg price target87.14 USD

Related research pages

Frequently asked questions

When is Vera Therapeutics (VERA)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for VERA. This page updates as the calendar is published.

Did VERA beat earnings last quarter?

In its 2026-05-07 report, VERA posted EPS of -1.69 USD versus a -1.32838 USD estimate — a miss of 27.2%.

What is VERA's earnings track record?

Over the last 5 reported quarters with consensus data, VERA beat estimates 1 times (20%).

What is VERA's current P/E ratio and EPS?

VERA trades at a trailing P/E of -6.51 on trailing EPS of -5.161871518921683 USD.

What do analysts rate VERA?

Analyst consensus is "Buy" across 14 ratings (1 strong buy, 12 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 87.14 USD.